CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates

Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) with respiratory failure; data expected in 1H 2026

Positive discussions with FDA on pivotal trial in acute pancreatitis (AP); final trial design expected in 1H 2026

Read more at prnewswire.com